Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

ce call to review financial results for the quarter and year ended December 31, 2007 and recent business developments. The call is scheduled for today, March 31, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). To participate in the live conference call, U.S. residents should dial 877-407-4018, and international callers should dial 201-689-8471. Alternatively, log on to http://www.imarx.com to access a live webcast of the call. Please connect to the Investor section of ImaRx's website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary. To access the 48-hour telephone replay, U.S. residents should dial 800-660-6853, and international callers should dial 201-612-7415. The account number for the event is 3055, and the conference ID number is 279436. A replay of the call will also be available on http://www.imarx.com 14-days following the call.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its first FDA-approved thrombolytic agent, urokinase, for the treatment of acute massive pulmonary embolism, or blood clot in the lungs. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary MRX-801 microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include: those related to the search for strategic alternatives
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... acute and chronic orthopedic conditions such as meniscal ... tennis elbow, and joint pain due to degenerative ... administered during orthopedic surgeries to promote better post-surgical ... advances in nearly pain-free bone marrow harvesting with ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... leading events organizer UBM Live announced details ... and opportunities across a broad spectrum of  India,s thriving ... InformexUSA, North America,s leading networking event for buyers and ... with the UBM team in India, InformexINDIA will be ...
... magic or legend, is slowly becoming reality. Over the ... working on devices that enable invisibility cloaks perhaps ... small objects from detection by microwaves or sound waves. ... international team working to understand invisibility and extend its ...
... California Institute for Nursing & Health Care (CINHC) released ... pilot New Graduate Nurse Transition to Practice Programs (RN ... San Francisco, found that the programs are making a ... graduates and increasing their employment opportunities in hospitals and ...
Cached Biology Technology:Informex Returns To India In 2012 2Informex Returns To India In 2012 3Mathematicians can conjure matter waves inside an invisible hat 2Study Shows Transition to Practice Programs Get Nurses Employed 2
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... of scientists has used gene therapy in two separate ... in monkeys and rats with a drug-induced form of ... scientific publications Brain and The Journal of Neuroscience, essentially ... onset and another strategy to treat the devastating side ...
... 2005 workshop in Tunisia, supported by the European ... in improving health in countries bordering the Mediterranean ... importance of Euro-Mediterranean partnerships in order to capitalise ... particular following the mapping of the human genome ...
... Research Center are analyzing the surprising results of the first ... , From January 2000 to July 2004, rainfall was excluded ... the Tapajós National Forest, in Brazil. A total of 6 ... 6' clear plastic panels suspended 3 to 12 feet above ...
Cached Biology News:Gene therapy for Parkinson's disease moves forward in animals 2Gene therapy for Parkinson's disease moves forward in animals 3Gene therapy for Parkinson's disease moves forward in animals 4Measuring the impact of post-genomics on Mediterranean populations 2World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3